PT2977 is an Orally Active and Selective HIF-2α Inhibitor for Solid Tumor Treatment
Previous studies have demonstrated that hypoxia-inducible factor 2α (HIF-2α) is a key oncogenic driver in clear cell renal cell carcinoma (ccRCC). PT2385 was the first reported HIF-2α inhibitor. However, PT2385…